Serina Therapeutics (SER) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $1.79, +4.68% vs the prior close of $1.71.
- Volume 27.40K shares, 0.4x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SER jumps 4.7% to $1.79. Closed at $1.79, +4.68% vs the prior close of $1.71. Day range $1.71–$1.94, opened at $1.71.
SER daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — SER jumps 4.7% to $1.79
- Closed at $1.79, +4.68% vs the prior close of $1.71. Day range $1.71–$1.94, opened at $1.71.
- Volume was 27.40K shares, 0.4x its 50-day average of 75.12K — lighter than usual.
- Price is -24.1% vs its 50-day average ($2.36) and -15.6% vs its 200-day average ($2.12).
- 52-week range $1.22–$5.29; today's close sits at 14% of that range, 66.2% below the 52-week high.
Oct 14, 2026 — SER slides 6.0% to $1.71, a 3-month low, 7 down days in a row
- Closed at $1.71, -6.04% vs the prior close of $1.82. Day range $1.71–$1.84, opened at $1.80.
- Volume was 46.30K shares, 0.6x its 50-day average of 75.09K.
- Price is -27.8% vs its 50-day average ($2.37) and -19.5% vs its 200-day average ($2.12).
- 52-week range $1.22–$5.29; today's close sits at 12% of that range, 67.7% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — SER slides 6.2% to $1.82, a 3-month low, 6 down days in a row
- Closed at $1.82, -6.19% vs the prior close of $1.94. Day range $1.78–$1.97, opened at $1.92.
- Volume was 26.30K shares, 0.4x its 50-day average of 74.92K — lighter than usual.
- Price is -23.4% vs its 50-day average ($2.38) and -14.5% vs its 200-day average ($2.13).
- 52-week range $1.22–$5.29; today's close sits at 15% of that range, 65.6% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — SER dips 3.0% to $1.94, a 3-month low on 1.8x normal volume
- Closed at $1.94, -3.00% vs the prior close of $2.00. Day range $1.90–$2.01, opened at $2.01.
- Volume was 132.20K shares, 1.8x its 50-day average of 72.47K — unusually heavy trading.
- Price is -18.5% vs its 50-day average ($2.38) and -9.0% vs its 200-day average ($2.13).
- 52-week range $1.22–$5.60; today's close sits at 16% of that range, 65.4% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — SER dips 0.5% to $2.00, 4 down days in a row
- Closed at $2.00, -0.50% vs the prior close of $2.01. Day range $1.99–$2.05, opened at $1.99.
- Volume was 22.30K shares, 0.3x its 50-day average of 72.27K — lighter than usual.
- Price is -16.0% vs its 50-day average ($2.38) and -6.3% vs its 200-day average ($2.13).
- 52-week range $1.22–$5.71; today's close sits at 17% of that range, 65.0% below the 52-week high.
- That makes 4 straight losses.
- SEC filings that day: 8-K.
Oct 8, 2026 — SER ends flat (+0.0%) to $2.01, 3 down days in a row
- Closed at $2.01, +0.00% vs the prior close of $2.01. Day range $1.99–$2.05, opened at $2.01.
- Volume was 59.30K shares, 0.8x its 50-day average of 71.21K.
- Price is -15.6% vs its 50-day average ($2.38) and -6.0% vs its 200-day average ($2.14).
- 52-week range $1.22–$5.83; today's close sits at 17% of that range, 65.5% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — SER dips 1.5% to $2.01
- Closed at $2.01, -1.47% vs the prior close of $2.04. Day range $2.01–$2.08, opened at $2.04.
- Volume was 12.90K shares, 0.2x its 50-day average of 71.50K — lighter than usual.
- Price is -15.7% vs its 50-day average ($2.38) and -6.1% vs its 200-day average ($2.14).
- 52-week range $1.22–$5.83; today's close sits at 17% of that range, 65.5% below the 52-week high.
Oct 6, 2026 — SER ends flat (+0.0%) to $2.04
- Closed at $2.04, +0.00% vs the prior close of $2.04. Day range $2.02–$2.08, opened at $2.03.
- Volume was 6.40K shares, 0.1x its 50-day average of 71.62K — lighter than usual.
- Price is -14.5% vs its 50-day average ($2.38) and -4.9% vs its 200-day average ($2.14).
- 52-week range $1.22–$5.83; today's close sits at 18% of that range, 65.0% below the 52-week high.
Oct 5, 2026 — SER jumps 4.1% to $2.04
- Closed at $2.04, +4.08% vs the prior close of $1.96. Day range $1.97–$2.10, opened at $2.10.
- Volume was 25.00K shares, 0.3x its 50-day average of 72.01K — lighter than usual.
- Price is -14.5% vs its 50-day average ($2.39) and -5.1% vs its 200-day average ($2.15).
- 52-week range $1.22–$5.83; today's close sits at 18% of that range, 65.0% below the 52-week high.
Oct 2, 2026 — SER rises 0.5% to $1.96
- Closed at $1.96, +0.51% vs the prior close of $1.95. Day range $1.95–$2.10, opened at $1.98.
- Volume was 15.20K shares, 0.2x its 50-day average of 72.47K — lighter than usual.
- Price is -17.9% vs its 50-day average ($2.39) and -9.0% vs its 200-day average ($2.15).
- 52-week range $1.22–$5.83; today's close sits at 16% of that range, 66.4% below the 52-week high.
SER latest news & SEC filings
Every SEC filing by or about SER in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
Sep 9, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 31, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 3.02 — Sold unregistered shares.
Aug 24, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 13, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $130.00K) (-100.0% vs Jun 30, 2025)
- Net income: -$6.36M (prior year -$6.45M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.55 (prior year -$0.66) (loss narrowed vs Jun 30, 2025)
Jul 23, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 23, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 22, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Brannan Stephen K. bought 1,000 shares at $2.03 (≈$2.03K) on Jul 7, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade SER
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 25, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.70% (largest 6.2%).
- Liquidity: about 84.81K shares (≈$151.81K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $1.79 vs a range of $1.22–$5.29 (14% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 7 open-market buys, 18 sales; latest: Stephen K. Brannan bought 1,000 shares on Jul 7, 2026.
- Latest filings: 8-K Oct 9, 2026; 8-K Sep 9, 2026; 8-K Aug 27, 2026.
- Share count: 25.40M shares outstanding (Aug 10, 2026), +147.8% vs a year earlier — notable dilution.
- Listing: NYSE · industry: Pharmaceutical Preparations.
SER market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 1.71 | 1.94 | 1.71 | 1.79 | 27.40K |
| Oct 14, 2026 | 1.80 | 1.84 | 1.71 | 1.71 | 46.30K |
| Oct 13, 2026 | 1.92 | 1.97 | 1.78 | 1.82 | 26.30K |
| Oct 12, 2026 | 2.01 | 2.01 | 1.90 | 1.94 | 132.20K |
| Oct 9, 2026 | 1.99 | 2.05 | 1.99 | 2.00 | 22.30K |
| Oct 8, 2026 | 2.01 | 2.05 | 1.99 | 2.01 | 59.30K |
| Oct 7, 2026 | 2.04 | 2.08 | 2.01 | 2.01 | 12.90K |
| Oct 6, 2026 | 2.03 | 2.08 | 2.02 | 2.04 | 6.40K |
| Oct 5, 2026 | 2.10 | 2.10 | 1.97 | 2.04 | 25.00K |
| Oct 2, 2026 | 1.98 | 2.10 | 1.95 | 1.96 | 15.20K |
| Oct 1, 2026 | 1.96 | 2.06 | 1.95 | 1.95 | 46.80K |
| Sep 30, 2026 | 2.09 | 2.09 | 2.00 | 2.00 | 10.80K |
| Sep 29, 2026 | 1.97 | 2.13 | 1.97 | 2.08 | 15.80K |
| Sep 28, 2026 | 2.08 | 2.20 | 2.00 | 2.01 | 1.02M |
| Sep 25, 2026 | 2.13 | 2.20 | 2.09 | 2.09 | 28.40K |
| Sep 24, 2026 | 2.19 | 2.30 | 2.14 | 2.14 | 76.30K |
| Sep 23, 2026 | 2.30 | 2.32 | 2.17 | 2.19 | 7.90K |
| Sep 22, 2026 | 2.28 | 2.43 | 2.16 | 2.31 | 23.80K |
| Sep 21, 2026 | 2.15 | 2.37 | 2.00 | 2.31 | 31.00K |
| Sep 18, 2026 | 2.20 | 2.29 | 2.09 | 2.25 | 65.10K |
About Serina Therapeutics
Serina Therapeutics (SER) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in HUNTSVILLE, AL. State of incorporation: AL. Fiscal year ends December 31. SEC CIK 1708599.
SER board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gregory Bailey | Director | Jun 22, 2026 |
| Stephen K. Brannan | Director | Jul 9, 2026 |
| Simba Gill | Director | Feb 17, 2026 |
| Steven A Ledger | Chief Executive Officer | May 27, 2026 |
| Richard Peter Marshall | Director | Jun 22, 2026 |
| Farrell Simon | Director | Jul 23, 2026 |
| Jay Venkatesan | Director | Jun 22, 2026 |
| Karen J Wilson | Director | Jun 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Gregory S Curhan | Chief Financial Officer | May 26, 2026 |
| Steven A Ledger | Chief Executive Officer | May 27, 2026 |
| Randall Moreadith | Chief Scientific Officer | May 26, 2026 |
| Srini Tenjarla | SVP, CMC & Formulation | May 26, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 7, 2026 | Stephen K. Brannan | Buy | 1,000 | $2.03 |
| Jun 12, 2026 | Karen J Wilson | Buy | 5,000 | $1.77 |
| Jun 11, 2026 | Karen J Wilson | Buy | 5,100 | $1.75 |
| May 22, 2026 | Karen J Wilson | Buy | 10,000 | $1.93 |
| May 22, 2026 | Jay Venkatesan | Buy | 589 | $1.78 |
| May 21, 2026 | Karen J Wilson | Buy | 10,000 | $1.77 |
| May 19, 2026 | Richard Peter Marshall | Buy | 12,183 | $1.65 |
| Mar 23, 2026 | Randall Moreadith | Sale | 6,500 | $2.86 |
| Mar 19, 2026 | Randall Moreadith | Sale | 39,000 | $2.50 |
| Feb 2, 2026 | Randall Moreadith | Sale | 6,500 | $3.03 |
| Jan 28, 2026 | Randall Moreadith | Sale | 6,500 | $3.57 |
| Jan 22, 2026 | Randall Moreadith | Sale | 2,500 | $2.95 |
| Jan 21, 2026 | Randall Moreadith | Sale | 2,000 | $3.00 |
| Jan 20, 2026 | Randall Moreadith | Sale | 2,000 | $3.07 |
| Jan 14, 2026 | Randall Moreadith | Sale | 1,084 | $2.50 |
SER financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $130.00K | $-19.18M | -1.91 | $-17.95M |
| Dec 31, 2024 | $56.00K | $-11.14M | -1.51 | $-17.14M |
| Dec 31, 2023 | $3.15M | $5.27M | 0.73 | $-2.48M |
| Dec 31, 2022 | $34.00K | $-10.46M | -9.70 | $-5.94M |
| Dec 31, 2021 | $144.00K | $-8.68M | — | $-7.86M |
Latest balance sheet: total assets $25.81M, total liabilities $7.08M, cash $23.02M (as of Jun 30, 2026).
SER earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $2.85 |
| May 14, 2026 | 8-K Item 2.02 (results) | $1.72 |
| Mar 25, 2026 | 8-K Item 2.02 (results) | $3.03 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $3.92 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $5.10 |
| May 8, 2025 | 8-K Item 2.02 (results) | $5.74 |
| Mar 24, 2025 | 8-K Item 2.02 (results) | $4.84 |
| Jan 6, 2025 | 8-K Item 2.02 (results) | $4.72 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $5.19 |
| Aug 9, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 22, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on SER
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.